Earnings report 📈 Stocks 🌍 Israel

Evogene Reports $0.8 Million Nine-Month Revenue Amid Pipeline Progress

Evogene posted a $10.5 million net loss for the first nine months of 2026 as it pivots toward internal AI-driven development programs, holding approximately $9.2 million in cash as of September 30.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: EVGN → 3/10 (50% confidence).

📊 Affected Assets (1)

EVGN
Neutral 🤖 50%
📅 Short-term 🌍 IL · Explicit

Nine-month revenues fell to ~$0.8 million from ~$3.2 million, mainly from Casterra and the end of the Bayer agreement, while consolidated cash stood at ~$9.2 million with ~$2.4 million used in Q3, though including a one-off ~$0.5 million D&O insurance payment covering 18 months. Offsetting this, the aGVHD program reached nanomolar potency candidates heading toward IND-enabling studies and AgPlenus fungicides cut Septoria disease severity by up to 75% in plant tissue assays. Promising pipeline progress versus a shrinking revenue base and modest cash leaves the net price effect unclear.

Catalysts
  • • Q3 2026 results published November 19, 2026
  • • AgPlenus compounds reducing Septoria disease severity by up to 75% in plant tissue assays
Risk Factors
  • • Revenues down ~$2.4 million year over year to ~$0.8 million
  • • Cash of ~$9.2 million with ~$2.4 million Q3 cash usage leaves a limited runway

🎯 Key Takeaways

  • Nine-month 2026 revenue fell to approximately $0.8 million, compared to $3.2 million in the same period of 2025.
  • Consolidated cash and equivalents stood at approximately $9.2 million as of September 30, 2026, with $2.4 million used during the third quarter.
  • AgPlenus fungicide compounds demonstrated up to 75% reduction in Septoria disease severity in plant tissue assays.
  • The company's aGVHD drug discovery program is advancing toward IND-enabling studies following the identification of nanomolar potency candidates.

📝 Executive Summary

Evogene Ltd. reported nine-month 2026 revenues of approximately $0.8 million, down from $3.2 million in the prior year, driven by the conclusion of its Bayer agreement and lower Casterra seed sales. Despite the revenue decline, the company is advancing its aGVHD drug discovery program toward IND-enabling studies and reported that AgPlenus fungicides reduced Septoria disease severity by up to 75% in plant tissue assays.

❓ FAQ

How much cash does Evogene have left?

As of September 30, 2026, Evogene held approximately $9.2 million in consolidated cash, cash equivalents and short-term bank deposits, and used about $2.4 million in cash during the third quarter, including a roughly $0.5 million D&O insurance payment covering an 18-month period.

Why did revenue drop so much?

Nine-month 2026 revenues were about $0.8 million versus about $3.2 million a year earlier, mainly because Casterra recognized about $2.0 million of seed sales in the first half of 2025 that did not repeat, and because the license and collaboration agreement with Bayer concluded in May 2026.